Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immix Biopharma, Inc. - Common Stock (NQ: IMMX ) 1.580 -0.010 (-0.63%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Immix Biopharma, Inc. - Common Stock < Previous 1 2 3 4 5 6 7 Next > Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 October 02, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board September 19, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 August 28, 2024 From Immix Biopharma, Inc. Via GlobeNewswire IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 August 12, 2024 IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 July 08, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum June 17, 2024 From Immix Biopharma, Inc. Via GlobeNewswire IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024 May 13, 2024 IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma April 29, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma on Track to Dose NXC-201 Patients in United States April 18, 2024 From Immix Biopharma, Inc. Via GlobeNewswire IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 April 02, 2024 IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial March 20, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative March 05, 2024 Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words From Immix Biopharma, Inc. Via GlobeNewswire BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering February 09, 2024 Via Investor Brand Network Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock February 08, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis February 07, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Proposed Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 25, 2024 Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 25, 2024 Via Benzinga Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products January 24, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board January 04, 2024 Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board December 18, 2023 From Immix Biopharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session December 15, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session December 14, 2023 Via Benzinga Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 December 11, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit November 30, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis November 22, 2023 Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing November 21, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients November 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients November 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
